Title
Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome.

Permalink
https://escholarship.org/uc/item/0kt6z58q

Journal
Journal of market access & health policy, 5(1)

ISSN
2001-6689

Authors
François, Clément
Stern, John M
Ogbonnaya, Augustina
et al.

Publication Date
2017

DOI
10.1080/20016689.2017.1318691

Peer reviewed
Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome

Clément François, John M. Stern, Augustine Ogbonnaya, Tasneem Lokhandwala, Pamela Landsman-Blumberg, Amy Duhig, Vivienne Shen and Robin Tan

*Health Economics and Outcomes Research, Lundbeck, LLC, Deerfield, IL, USA; **Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA; Scientific Consulting, Xcenda, LLC, Palm Harbor, FL, USA

ABSTRACT

**Background:** Lennox-Gastaut syndrome (LGS) is a severe form of childhood-onset epilepsy associated with serious injuries due to frequent and severe seizures. Of the antiepileptic drugs (AEDs) approved for LGS, clobazam is a more recent market entrant, having been approved in October 2011. Recent AED budget impact and cost-effectiveness analyses for LGS suggest that adding clobazam to a health plan formulary may result in decreased medical costs; however, research on clinical and economic outcomes and treatment patterns with these AED treatments in LGS is limited.

**Objectives:** To compare the baseline characteristics and treatment patterns of new initiators of clobazam and other AEDs among LGS patients and compare healthcare utilization and costs before and after clobazam initiation among LGS patients.

**Methods:** A retrospective study of probable LGS patients was conducted using the MarketScan® Commercial, Medicare Supplemental, and Medicaid databases (10/1/2010-3/31/2014).

**Results:** In the Commercial/Medicare Supplemental population, clobazam users were younger, had fewer comorbidities, and more prior AED use than non-clobazam users. In the 12 months pre-treatment initiation, clobazam users had significantly more seizure-related inpatient stays and outpatient visits and higher total seizure-related costs than non-clobazam users. Among clobazam users, when compared to the 12 months pre-clobazam initiation, seizure-related medical utilization and costs were lower in the 12 months post-clobazam initiation (P < 0.001) and seizure-related (P = 0.029) costs increased post-clobazam initiation mainly due to the increase in outpatient pharmacy costs. Similar results were observed in the Medicaid population.

**Conclusions:** Baseline results suggest a prescribing preference for clobazam in severe LGS patients. Clobazam users had a reduction in seizure-related medical utilization and costs after clobazam initiation. The improvement in medical costs mostly offset the higher prescription costs following clobazam initiation.

Background

Lennox-Gastaut syndrome (LGS) is a severe type of epilepsy with onset in childhood and characterized by intellectual disability, specific electroencephalographic abnormalities, and frequent generalized-onset or sometimes focal-onset seizures [1]. LGS typically develops before eight years of age, with occurrence rates peaking between three and five years of age; however, late cases in early adulthood have also been reported [1]. Estimated to account for 1–10% of all childhood epilepsies, LGS has a mortality rate between 4% and 7% in patients younger than 11 years of age [2–4].

LGS can have a major physical impact due to frequent and severe seizures that increase the likelihood of fall-related injuries. Seizures during the childhood development stage can halt cognitive and social development and lead to behavioral impairment [1,5]. Cognitive impairment is seen in 75–95% of patients five years after condition onset, and 90% will eventually become intellectually disabled [5,6]. Additionally, LGS has a significant impact on the health-related quality of life of not only the patient but also their caregiver [7].

Six antiepileptic drugs (AEDs) have been approved to date by the United States Food and Drug Administration (FDA) for the treatment of LGS: clobazam; clonazepam; felbamate; lamotrigine; topiramate; and rufinamide. Valproate and clorazepate, which are not approved by the FDA for LGS treatment, are...
Clobazam has demonstrated both short- and long-term efficacy in children, adolescents, and adults, and is well tolerated across all ages [10]. Recent AED budget impact and cost-effectiveness analyses for LGS suggest that adding clobazam to a health plan formulary may have a positive overall budget impact through decreased medical costs, as clobazam has been proven efficacious in the treatment of drop seizures, which are a major cause of morbidity and healthcare utilization among these patients [11,12]. Clobazam has specifically been shown to be more effective and less costly than rufinamide over a two-year period [11].

Currently, there is limited research on clinical and economic outcomes and a lack of information on treatment patterns with the aforementioned AED treatments in LGS. Therefore, this study had two objectives: (1) to describe the baseline characteristics and treatment patterns of LGS patients treated with clobazam compared to other AED treatments; and (2) to compare healthcare resource utilization and costs before and after treatment among clobazam users.

Methods

Study design

This retrospective longitudinal cohort study used administrative claims data with dates of service from 1 October 2010 through 31 March 2014. The date treatment of interest initiated was set to be the index date. The study enrollment period was between 1 October 2011 and 30 September 2013, allowing a 12-month pre-treatment initiation period (i.e., pre-index) and a minimum six-month post-treatment initiation (i.e., post-index) period.

Data source

This study was conducted using three Truven Health MarketScan® claims databases [12]: the Commercial Claims and Encounters Database (Commercial); the Medicare Supplemental and Coordination of Benefits Database (Medicare Supplemental); and the Medicaid Multi-state Database (Medicaid). The Commercial database consists of employer- and health plan-sourced data containing medical and drug claims for over 40 million individuals annually. The Medicare Supplemental database contains the medical and prescription claims of Medicare-eligible persons with supplemental insurance offered by their former employers. There are approximately 4.3 million enrollees annually included in the database. For the purposes of these analyses, the Commercial and Medicare Supplemental databases were combined and a single unique identifier allows for patients to be followed as they move from a Commercial payer to Medicare. The Medicaid database contains the medical and prescription drug experience of Medicaid enrollees in both fee-for-service and managed-care plans pooled from 10 to 13 states annually.

Patient identification

Criteria used to identify patients with LGS were based on a previously published algorithm [13] and clinical input (John M. Stern and Vivienne Shen), and are as follows: (1) ≥2 medical claims with a diagnosis of generalized convulsive seizures (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM: 345.1x]) or non-convulsive epilepsy (ICD-9-CM: 345.0x) that are ≥30 days apart, or ≥1 medical claim with a diagnosis of generalized convulsive epilepsy (ICD-9-CM: 345.1x) and ≥1 medical claim with a diagnosis of non-convulsive epilepsy (ICD-9-CM: 345.0x) that are ≥30 days apart; (2) ≥1 of the epilepsy diagnosis codes had to be in the primary position; (3) ≥1 medical claim with a diagnosis for developmental disorder or cognitive impairment (ICD-9-CM: 299.80, 299.81, 299.90, 299.91, 294.8x, 294.9x, 315.39, 315.4x, 315.5x, 315.8x, 315.9x, 316.xx, 317.xx, 318.0x, 318.1x, 318.2x, 319.xx, 348.3x, 348.89, 780.97, and 783.4x) in any position during the enrollment window.

Based on the AED treatment initiated during the enrollment window and after the first evidence of LGS diagnosis, patients were further classified into one of two mutually exclusive treatment groups: clobazam or non-clobazam. Patients in the clobazam cohort initiated treatment with clobazam, and may have received prior treatment with another AED. The date of the first clobazam prescription fill was deemed the index date. Patients in the non-clobazam cohort initiated treatment with another AED (clonazepam, felbamate, lamotrigine, rufinamide, topiramate, valproate, or clorazepate). To qualify as the index prescription, the patient had to be naive to that particular AED (i.e., have no other prescription claims for that AED in the prior 12 months); otherwise, the subsequent AED prescription was evaluated similarly. Lastly, patients must have continuous enrollment in medical and pharmacy benefits for ≥12 months prior to and ≥6 months after the index date. For the pre- and post-clobazam healthcare resource utilization and cost comparison, clobazam
patients had to have ≥12 months of post-index continuous enrollment. Patients were excluded if they did not have a qualifying AED prescription during the enrollment window or if they were dually eligible for both Medicare and Medicaid, as prescription claims were not available for these patients.

**Study measures**

**Demographic and clinical characteristics**

Demographic characteristics, including age, gender, race (Medicaid only), geographic region (Commercial/Medicare Supplemental only), urban/rural, plan type (Commercial/Medicare Supplemental only), payer type (Commercial/Medicare Supplemental only), capitation, reason for eligibility (Medicaid only), length of follow-up, and year of index date, were measured on index for each patient. Pre-index clinical characteristics included use of medication classes (other seizure medications, anxiolytics, antipsychotics, and hypnotics), number of medication classes used, number of AED drugs of interest, and comorbidities.

**Healthcare resource utilization and costs**

Healthcare resource utilization and costs were conducted from the perspective of a private or governmental insurance plan in the United States. Per-patient all-cause and seizure-related healthcare resource utilization and their associated costs were reported by treatment setting (e.g., inpatient, emergency room [ER], physician office, laboratory, radiology, other outpatient, and pharmacy) during the pre-index period and also for the clobazam cohort during the post-index period. All-cause resource utilization included all medical and pharmacy services for any reason during the time period of interest. Medical resource utilization was deemed to be seizure-related if the primary ICD-9-CM diagnosis code on a claim was 345.0x–345.9x, and seizure-related pharmacy services included all prescriptions for the AEDs of interest and other seizure-related medications (Table 1). All-cause healthcare costs were costs associated with all utilizations, while seizure-related healthcare costs were costs for all seizure-related utilizations. Costs reflected all payments made to providers of care from both the plan (plan and coordination of benefits) and the patient (copayment, coinsurance, deductible). All costs were adjusted to 2014 United States dollars (USD) using the medical care component of the Bureau of Labor Statistics’ Consumer Price Index.

**Treatment patterns**

Treatment patterns were assessed for both study cohorts during the post-index period and included the number of index AED prescription claims, total days on index drug and all AEDs, changes to the index treatment (i.e., augmentation, switching, discontinuation), and discontinuation from all AEDs. Augmentation was defined as a prescription fill for an alternative AED treatment (one of the seven non-index AEDs) while continuing to fill prescriptions for the index AED. Switching was defined as a prescription fill for a new AED that was different from the index agent, with no further prescription fills for the index AED. Discontinuation from index treatment and from all AEDs was defined as a >30-day period without evidence of having the index AED and or any AEDs on hand respectively.

**Statistical analyses**

Separate analyses were conducted for the combined Commercial and Medicare Supplemental and Medicaid populations.

| Medication/medication class | Generic name (brand) |
|----------------------------|---------------------|
| AMPA receptor antagonist   | Perampanel (Fycompa) |
| SVP2a binder              | Levetiracetam (Keppra, Keppra XL) |
| Carbonic anhydrase inhibitor | Acetazolamide (Diamox) |
| Sodium channel inhibitor | Carbamazepine (Tegretol), Eslicarbazepine (Aptiom), Oxcarbazepine (Trileptal), Rufinamide (Banzel) |
| GABA analogues             | Gabapentin (Neurontin), Pregabalin (Lyrica), Progabide (Gabrene), Vigabatrin (Sabril) |
| GABA reuptake inhibitors   | Tiagabine (Gabitril) |
| K-channel opener           | Ezogabine/Retigabine (Potiga) |
| NMDA receptor blockers     | Felbamate (Felbatol), Sodium Channel Modulators, Lacosamide (Vimpat), Lamotrigine (Lamictal), Phenytoin (Dilantin) |
| T-type calcium channel     | Ethosuximide (Zarontin), Methsuximide (Celontin) |
| Sulfamate-substituted monosaccharides | Topiramate (Topamax, Topamax ER, Qudexy XR) |
| Sodium channel             | Zonisamide (Zonegran) |
| Valproic acid              | Divalproex Sodium (Depakote), Valproic Acid (Depakene) |
| Barbiturates               | Phenobarbital, Primidone (Mysoline) |
| Benzodiazepines            | Clonazepam (Onfi), Clonazepam (Klonopin, Epitril, Rivotril), Clorazepate Dipotassium (Tranxene), Diazepam (Valium, Diastat), Lorazepam (Ativan) |

Notes: GABA – gamma aminobutyric acid; NMDA – N-methyl-D-aspartate; SVP2a – synaptic vesicle protein 2A.
Clobazam vs non-clobazam cohorts
Descriptive statistics (percentages, means, medians, standard deviations) were used to describe the baseline characteristics of the clobazam and non-clobazam cohorts. Statistical comparison of baseline measures was conducted using chi-squared tests for categorical measures and Student’s t-tests or Mann-Whitney tests for continuous measures, as appropriate to the underlying distribution. To create comparability of the baseline demographic and clinical characteristics of clobazam and non-clobazam users for treatment pattern comparisons, standardized mortality ratio weighting, a propensity score (PS) technique, was employed in order to ameliorate selection bias prior to comparison of outcomes [14]. PS for each patient was estimated using a logistic regression model that included patients’ baseline characteristics as the independent variables and treatment as the dependent variable. Weights were computed as follows: 1 (PS/PS) for clobazam users and PS/(1 – PS) for the non-clobazam users.

As baseline characteristics between the clobazam and non-clobazam cohorts remained unbalanced, for treatment patterns during the post-index period, descriptive statistics were presented for the clobazam and non-clobazam cohorts, and no statistical comparison was performed.

Healthcare resource utilization and costs pre- and post-clobazam initiation
Among the clobazam cohort, healthcare resource utilization, and costs pre- and post-treatment initiation were compared. Statistical differences in categorical measures were analyzed using McNemar’s tests, count measures using paired t-tests, and costs using Wilcoxon signed-rank tests.

Results
Baseline demographic characteristics
A total of 44,921 Commercial/Medicare Supplemental patients and 19,110 Medicaid patients with evidence of epilepsy were identified during the enrollment window (Figure 1). After applying the study inclusion and exclusion criteria, the final Commercial/Medicare population consisted of 1974 LGS patients, with 590 (29.9%) clobazam users and 1384 (70.1%) non-clobazam users. The Medicaid population consisted of 2012 LGS patients, with 647 (32.2%) clobazam users and 1365 (67.8%) non-clobazam users. The average age of the Commercial/Medicare Supplemental population was 26.1 years (standard deviation [SD]: 21.9) and 50.9% were males (Table 2). Patients in the clobazam cohort were younger (14.8 ± 12.5 vs 31.0 ± 23.2, \(P < 0.001\)) and a higher proportion were males compared to the non-clobazam cohort (54.6% vs 49.3%, \(P = 0.034\)). The average age of the Medicaid population was 20.7 (±16.8) years old and 51.6% were males (Table 3). Clobazam users were again younger compared to non-clobazam users (13.7 ± 11.4 vs 24.1 ± 17.9, \(P < 0.001\)).

Baseline clinical characteristics
Among the Commercial/Medicare Supplemental patients, compared to the non-clobazam cohort, higher proportions of the clobazam cohort had pre-index prescription fills for AEDs and other seizure-related medications (95.8% vs 77.1%, \(P < 0.001\)) and anxiolytics (35.1% vs 28.8%, \(P = 0.006\)), and a lower proportion had pre-index prescription fills for antipsychotics (10.3% vs 14.8%, \(P = 0.008\)) (Table 2). The clobazam cohort also had evidence of using a higher number of unique AED agents (1.7 ± 1.1 vs 0.5 ± 0.7, \(P < 0.001\)) and a lower number of non-AED prescription classes (5.8 ± 4.9 vs 6.6 ± 6.2, \(P = 0.002\)) prior to index. Significant differences were observed in the majority of comorbidities assessed, with the prevalence being lower in the clobazam cohort than in the non-clobazam cohort, with the following exceptions: tuberous sclerosis (2.7% vs 0.3%; \(P < 0.001\)), cortical dysplasia (3.1% vs 1.2%, \(P = 0.005\)), intellectual disorder (25.1% vs 11.3%, \(P < 0.001\)), eating disorder (17.8% vs 5.8%, \(P < 0.001\)), and digestive/bowel disorder (39.0% vs 33.2%, \(P = 0.014\)).

Among LGS Medicaid patients, baseline use of AEDs, other seizure-related medications, and non-AEDs was similar to that observed in the Commercial/Medicare Supplemental patients, with the exception that the clobazam cohort had claims for a similar number of pre-index non-AED prescription classes as the non-clobazam cohort. Baseline comorbidity differences were similar to the Commercial/Medicare Supplemental population with one exception: there was no significant difference in the baseline rates of digestive/bowel disorder between the cohorts.

Baseline seizure-related resource utilization and costs
Commercial/Medicare Supplemental clobazam users had higher pre-index seizure-related resource utilization and associated costs compared to non-clobazam users (Table 4). Higher proportions of clobazam users had
least one seizure-related hospitalization (36.8% vs 27.5%, \(P < 0.001\)), physician office visit (94.6% vs 78.1%, \(P < 0.001\)), neurologist visit (58.8% vs 52.7%, \(P = 0.012\)), laboratory visit (43.1% vs 19.8%, \(P < 0.001\)), and other outpatient visit (67.5% vs 46.2%, \(P < 0.001\)). Clobazam users also had higher average seizure-related total inpatient length of stay (LOS) (2.6 ± 7.6 days vs 1.4 ± 4.7 days, \(P = 0.001\)) and higher average numbers of seizure-related visits by setting of care than non-clobazam users.

The higher seizure-related resource utilization among the clobazam cohort led to higher average annual seizure-related costs over the pre-index period. Average annual pre-index seizure-related total ($33,478 ± $58,431 vs $12,709 ± $36,420, \(P < 0.001\)), medical ($24,066 ± $56,142 vs $10,563 ± $35,194, \(P < 0.001\)), and prescription ($9411 ± $12,416 vs $2146 ± $5596, \(P < 0.001\)) costs were significantly higher for clobazam users compared to non-clobazam users. Pre-index average medical costs by setting of care among patients in the clobazam cohort were two to four times greater than those of the non-clobazam cohort.

Medicaid clobazam users also had higher seizure-related resource utilization, on average, over the 12-month pre-index period compared to non-clobazam users (Table 4), with two exceptions. Unlike the Commercial/Medicare Supplemental patients, no significant differences were observed between the proportion of patients with a seizure-related neurologist visit or in the number of primary care provider (PCP) visits. Overall, pre-index cost differences were similar to the Commercial/Medicare Supplemental population, except there were no significant differences between the clobazam and non-clobazam cohorts in the cost of seizure-related neurologist visits.
## Table 2. Baseline demographic and clinical characteristics of commercial/Medicare Supplemental patients.

| Demographic characteristics | Clobazam N = 590 | Non-clobazam N = 1384 | P-value* |
|-----------------------------|-------------------|------------------------|----------|
| **Age in years, mean (SD)** | 14.8 (12.5)       | 31.0 (23.2)            | **<0.001** |
| **Age group in years, n (%)** |                   |                        |          |
| 0–5                         | 117 (19.8%)       | 116 (8.4%)             | **<0.001** |
| 6–12                        | 221 (37.5%)       | 266 (19.2%)            |          |
| 13–17                       | 84 (14.2%)        | 165 (11.9%)            |          |
| 18–34                       | 120 (20.3%)       | 314 (22.7%)            |          |
| 35–44                       | 21 (3.6%)         | 117 (8.5%)             |          |
| 45–54                       | 15 (2.5%)         | 129 (9.3%)             |          |
| 55–64                       | 8 (1.4%)          | 131 (9.5%)             |          |
| 65+                         | 4 (0.7%)          | 146 (10.5%)            |          |
| **Males, n (%)**            | 322 (54.6%)       | 683 (49.3%)            | **0.034** |
| **Geographic region, n (%)** |                   |                        |          |
| Northeast                   | 138 (23.4%)       | 309 (22.3%)            | 0.41     |
| North central               | 139 (23.6%)       | 280 (20.2%)            |          |
| South                       | 179 (30.3%)       | 461 (33.3%)            |          |
| West                        | 118 (20.0%)       | 290 (21.0%)            |          |
| Unknown                     | 16 (2.7%)         | 44 (3.2%)              |          |
| **Urban, n (%)**            | 529 (89.7%)       | 1224 (88.4%)           | 0.431    |
| **Plan type, n (%)**        |                   |                        | **<0.001** |
| FFS                         | 11 (1.9%)         | 97 (7.0%)              |          |
| EPO/PPO                     | 379 (64.2%)       | 891 (64.4%)            |          |
| HMO                         | 73 (12.4%)        | 164 (11.8%)            |          |
| POS                         | 49 (8.3%)         | 76 (5.5%)              |          |
| CDHP/HDHP                   | 57 (9.7%)         | 112 (8.1%)             |          |
| Unknown                     | 21 (3.6%)         | 44 (3.2%)              |          |
| **Payer type, n (%)**       |                   |                        | **<0.001** |
| Commercial                  | 585 (99.2%)       | 1223 (88.4%)           |          |
| Medicare                    | 5 (0.8%)          | 161 (11.6%)            |          |
| **Index year, n (%)**       |                   |                        | **<0.001** |
| 2011                        | 2 (0.3%)          | 122 (8.8%)             |          |
| 2012                        | 421 (71.4%)       | 737 (53.3%)            |          |
| 2013                        | 167 (28.3%)       | 525 (37.9%)            |          |
| **Clinical characteristics** |                   |                        |          |
| **Baseline medication classes, b n (%)** | 565 (95.8%) | 1067 (77.1%) | **<0.001** |
| AEDs and other seizure-related medications | 364 (61.7%) | 289 (20.9%) | **<0.001** |
| Benzodiazepines             | 304 (51.5%)       | 361 (26.1%)            | **<0.001** |
| NMDA receptor blockers      | 268 (45.4%)       | 595 (43.0%)            | 0.319    |
| SVP2a binder                | 240 (40.7%)       | 170 (12.3%)            | **<0.0001** |
| Valproic acid               | 192 (32.5%)       | 205 (14.8%)            | **<0.001** |
| Sodium channel inhibitor    | 139 (23.6%)       | 122 (8.8%)             | **<0.001** |
| Sulfamate-substituted monosaccharide | 105 (17.8%) | 100 (7.2%) | **<0.001** |
| Zonisamide                  | 51 (8.6%)         | 131 (9.5%)             | 0.564    |
| GABA analogues              | 36 (6.1%)         | 58 (4.2%)              | 0.068    |
| **Number of unique prescription classes (non-AEDs), mean (SD)** | 5.8 (4.9) | 6.6 (6.2) | **0.002** |
| **Number of pre-index AED drugs of interest, mean (SD)** | 1.7 (1.1) | 0.5 (0.7) | **<0.001** |
| **Baseline comorbidities, c n (%)** | 221 (37.5%) | 797 (57.6%) | **<0.001** |
| Pain                        | 230 (39.0%)       | 460 (33.2%)            | 0.014    |
| Constipation                | 142 (24.1%)       | 516 (37.3%)            | **<0.001** |
| Psychosis                   | 54 (9.2%)         | 377 (27.2%)            | **<0.001** |
| Migraine/headache           | 148 (25.1%)       | 156 (11.3%)            | **<0.001** |
| Intellectual disorder       | 13 (2.2%)         | 27 (2.0%)              | 0.716    |
| Mild                        | 14 (2.4%)         | 26 (1.9%)              | 0.476    |
| Moderate                    | 58 (9.8%)         | 46 (3.3%)              | **<0.001** |
| Other                       | 101 (17.1%)       | 100 (7.2%)             | **<0.001** |
| Anxiety                     | 35 (5.9%)         | 289 (20.9%)            | **<0.001** |
| Depression                  | 25 (4.2%)         | 289 (20.9%)            | **<0.001** |
| Behavioral disorder         | 134 (19.3%)       | 235 (17.0%)            | 0.212    |
| Eating disorder             | 105 (17.8%)       | 80 (5.8%)              | **<0.0001** |
| Sleep disorder              | 93 (15.8%)        | 238 (17.2%)            | 0.435    |

(Continued)
### Table 2. (Continued).

|                          | Clobazam     | Non-clobazam | P-value\(^a\) |
|--------------------------|--------------|--------------|---------------|
| Walking/gait impairment  | 77 (13.1%)   | 160 (11.6%)  | 0.351         |
| Cognitive disorder       | 42 (7.1%)    | 213 (15.4%)  | <0.001        |
| Stroke/TIA               | 9 (1.5%)     | 179 (12.9%)  | <0.001        |
| Arthritis                | 9 (1.5%)     | 157 (11.3%)  | <0.001        |
| ADHD                     | 44 (7.5%)    | 96 (6.9%)    | 0.680         |
| Obesity                  | 03 (5.0%)    | 82 (5.9%)    | <0.001        |

Notes: ADHD – attention deficit hyperactivity disorder; AED – antiepileptic drug; CDHP – consumer-driven health plan; EPO – exclusive provider organization; FFS – fee-for-service; GABA – gamma aminobutyric acid; GI – gastrointestinal; GP – general practitioner; HDHP – high-deductible health plan; HMO – health maintenance organization; NMDA – N-methyl-D-aspartate; POS – point of service; PPO – preferred provider organization; SD – standard deviation; SVP2a – synaptic vesicle protein 2A; TIA – transient ischemic attack.

\(^a\) P < 0.05. P-values were obtained using Chi-square tests for categorical variables and t-tests for continuous variables. Fisher’s exact test was used where Chi-square test was not valid due to cells having fewer than expected counts.

### Table 3. Baseline demographic and clinical characteristics of Medicaid patients.

|                          | Clobazam     | Non-clobazam | P-value\(^a\) |
|--------------------------|--------------|--------------|---------------|
| Demographic characteristics |              |              |               |
| Age in years, mean (SD)  | 13.7 (11.4)  | 24.1 (17.9)  | <0.001        |
| Age group in years, n (%)|              |              |               |
| 0–5                      | 165 (25.5%)  | 208 (15.2%)  | <0.001        |
| 6–12                     | 206 (31.8%)  | 267 (19.6%)  |               |
| 13–17                    | 101 (15.6%)  | 157 (11.5%)  |               |
| 18–34                    | 134 (20.7%)  | 342 (25.1%)  |               |
| 35–44                    | 21 (3.2%)    | 141 (10.3%)  |               |
| 45–54                    | 12 (1.9%)    | 144 (10.5%)  |               |
| 55–64                    | 8 (1.2%)     | 106 (7.8%)   |               |
| Males, n (%)             | 331 (51.2%)  | 707 (51.8%)  | 0.790         |
| Race, n (%)              |              |              |               |
| White                    | 348 (53.8%)  | 691 (50.6%)  | <0.001        |
| Black                    | 80 (12.4%)   | 307 (22.5%)  |               |
| Hispanic                 | 35 (5.4%)    | 48 (3.5%)    |               |
| Other/unknown            | 184 (28.4%)  | 319 (23.4%)  |               |
| Capitation, n (%)        |              |              |               |
| Yes                      | 183 (28.3%)  | 450 (33.0%)  | 0.035         |
| No                       | 464 (71.7%)  | 915 (67.0%)  |               |
| Reason for Medicaid eligibility, n (%) | 531 (82.1%) | 960 (70.3%) | <0.001 |
| Blind/disabled individual | 531 (82.1%) | 960 (70.3%) | <0.001 |
| Child (not of unemployed adult/not foster care) | 73 (11.3%) | 207 (15.2%) | <0.001 |
| Other\(^b\)              | 43 (6.6%)    | 198 (14.5%)  |               |
| Index year, n (%)        |              |              |               |
| 2011                     | 2 (0.3%)     | 133 (9.7%)   | <0.001        |
| 2012                     | 478 (73.9%)  | 846 (62.0%)  |               |
| 2013                     | 167 (25.8%)  | 386 (28.3%)  |               |
| Clinical characteristics  |              |              |               |
| Developmental and cognitive disorders, n (%) | 597 (92.3%) | 1130 (82.8%) | <0.001 |
| Number of unique diagnoses, mean (SD) | 3.0 (2.0) | 2.0 (1.7) | <0.001 |
| Baseline medication classes,\(^c\) n (%) | 633 (97.8%) | 1116 (81.8%) | <0.001 |
| AEDs and other seizure-related medications | 429 (66.3%) | 404 (29.6%) | <0.001 |
| Benzodiazepine           | 310 (47.9%)  | 384 (28.1%)  | <0.001        |
| NMDA receptor blocker    | 306 (47.3%)  | 568 (41.6%)  | 0.016         |
| SVP2a binder             | 236 (36.5%)  | 209 (15.3%)  | <0.001        |
| Valproic acid            | 217 (33.5%)  | 289 (21.2%)  | <0.001        |
| Sodium channel inhibitor | 176 (27.2%)  | 158 (11.6%)  | <0.001        |
| Sulfamate-substituted monosaccharide | 146 (22.6%) | 107 (7.8%)  | <0.001        |
| Zonisamide               | 49 (7.6%)    | 136 (10.0%)  | 0.083         |
| GABA analogue            | 233 (36.0%)  | 401 (29.4%)  | 0.003         |
| Anxiolytics              | 93 (14.4%)   | 329 (24.1%)  | <0.001        |
| Antipsychotics           | 116 (17.9%)  | 211 (15.5%)  | 0.161         |
| Number of unique prescription classes (non-AEDs), mean (SD) | 7.6 (5.9) | 7.8 (6.9) | 0.444 |
| Number of pre-index AED drugs of interest, mean (SD) | 1.7 (1.1) | 0.5 (0.7) | <0.001 |
| Baseline comorbidities,\(^d\) n (%) | 633 (97.8%) | 1116 (81.8%) | <0.001 |

(Continued)
### Table 3. (Continued).

| Condition                          | Clobazam (N = 647) | Non-clobazam (N = 1365) | P-value\(^a\) |
|-----------------------------------|---------------------|--------------------------|---------------|
| Pain                              | 284 (43.9%)         | 813 (59.6%)              | <0.001        |
| Intellectual disorder             | 324 (50.1%)         | 481 (35.2%)              | <0.001        |
| Mild                              | 61 (9.4%)           | 144 (10.6%)              | 0.437         |
| Moderate                          | 90 (13.9%)          | 138 (10.1%)              | 0.012         |
| Severe/profound                   | 135 (20.9%)         | 162 (11.9%)              | <0.001        |
| Other                             | 214 (33.1%)         | 307 (22.5%)              | <0.001        |
| Any digestive/bowel disorder      | 301 (46.5%)         | 587 (43.0%)              | 0.138         |
| Constipation                      | 158 (24.4%)         | 244 (17.9%)              | 0.001         |
| Anxiety                           | 48 (7.4%)           | 318 (23.3%)              | <0.001        |
| Eating disorder                   | 123 (19.0%)         | 104 (7.6%)               | <0.001        |
| Sleep disorder                    | 106 (16.4%)         | 252 (18.5%)              | 0.255         |
| Cognitive disorder                | 58 (9.0%)           | 211 (15.5%)              | <0.001        |
| ADHD                              | 60 (9.3%)           | 173 (12.7%)              | 0.026         |
| Walking/gait impairment           | 74 (11.4%)          | 150 (11.0%)              | 0.765         |
| Obesity                           | 29 (4.5%)           | 134 (9.8%)               | <0.001        |
| Arthritis                         | 12 (1.9%)           | 132 (9.7%)               | <0.001        |
| Stroke/TIA                        | 18 (2.8%)           | 96 (7.0%)                | <0.001        |

Notes: ADHD – attention deficit hyperactivity disorder; AED – antiepileptic drug; GI – gastrointestinal; GP – general practitioner; NMDA – N-methyl-D-aspartate; SD – standard deviation; SVP2a – synaptic vesicle protein 2A; TIA – transient ischemic attack.

\(^a\) P < 0.05. P-values were obtained using Chi-square tests for categorical variables and t-tests for continuous variables. Fisher’s exact test was used where Chi-square test was not valid due to cells having fewer than expected counts.

\(^b\) Other includes aged individual, adult (not based on unemployed status), foster care child, and eligibility status unknown.

\(^c\) Less than 5% of patients in both cohorts received T-type calcium channel, GABA reuptake inhibitor, barbiturate, carbonic anhydrase inhibitor, and K-channel opener.

\(^d\) Less than 5% of patients in both cohorts had a diagnosis of cortical dysplasia, tuberous sclerosis, brain lesions, heart failure, chronic renal disease, and coronary heart disease.

Bold text indicates a statistically significant difference with a p-value < 0.05.

### Table 4. Baseline healthcare utilization of commercial/Medicare Supplemental patients and Medicaid patients.

| Healthcare Utilization | Commercial/Medicare Supplemental | Medicaid | P-value\(^a\) |
|------------------------|----------------------------------|----------|---------------|
|                       | Clobazam (N = 647)              | Non-clobazam (N = 1365) | P-value\(^a\) |
| Hospitalization, n (%) | 217 (36.8%)                      | 381 (27.5%) | <0.001        |
| Number of inpatient visits, mean (SD) | 0.7 (1.3) | 0.4 (0.8) | <0.001 | 0.5 (1.1) | 0.3 (0.8) | <0.001 |
| LOS, mean (SD)         | 2.6 (7.6)                        | 1.4 (4.7) | <0.001        | 2.2 (6.7) | 1.4 (6.0) | 0.010 |
| ER visits, n (%)       | 177 (30.0%)                      | 418 (30.2%) | <0.001        | 232 (35.9%) | 539 (39.5%) | 0.118 |
| Number of ER visits, mean (SD) | 0.6 (1.3) | 0.5 (1.0) | 0.021 | 0.8 (2.0) | 0.9 (1.8) | 0.365 |
| Physician office visits, n (%) | 558 (94.6%) | 1081 (78.1%) | <0.001 | 1033 (75.7%) | 305 (57.8%) | <0.001 |
| Number of physician office visits, mean (SD) | 3.9 (3.5) | 2.2 (2.3) | <0.001 | 3.5 (3.2) | 2.1 (2.2) | <0.001 |
| Neurologist visit, n (%) | 347 (58.8%)                      | 729 (52.7%) | 0.012 | 60 (9.3%) | 99 (7.3%) | 0.117 |
| Number of neurologist visits, mean (SD) | 1.8 (2.2) | 1.3 (1.7) | <0.001 | 0.3 (1.1) | 0.2 (0.8) | 0.024 |
| PCP visit, n (%)       | 115 (19.5%)                      | 236 (17.1%) | 0.194 | 177 (27.4%) | 390 (28.6%) | 0.572 |
| Number of PCP visits, mean (SD) | 0.5 (1.6) | 0.3 (1.0) | 0.010 | 0.8 (1.8) | 0.7 (1.5) | 0.304 |
| Laboratory visits, n (%) | 254 (43.1%)                      | 274 (19.8%) | <0.001 | 225 (16.5%) | 244 (18.5%) | <0.001 |
| Number of laboratory visits, mean (SD) | 1.1 (2.2) | 0.3 (0.9) | <0.001 | 0.5 (1.2) | 0.3 (0.9) | <0.001 |
| Radiology visits, n (%) | 58 (9.8%)                        | 110 (8.0%) | 0.170 | 55 (8.5%) | 113 (8.3%) | 0.866 |
| Number of radiology visits, mean (SD) | 0.1 (0.4) | 0.1 (0.3) | 0.052 | 0.1 (0.4) | 0.1 (0.4) | 0.830 |
| Other outpatient visits, n (%) | 398 (67.5%)                      | 640 (46.2%) | <0.001 | 588 (43.1%) | 483 (34.8%) | <0.001 |
| Number of other outpatient visits, mean (SD) | 7.1 (23.2) | 1.8 (11.5) | <0.001 | 10.3 (38.3) | 4.7 (27.6) | 0.001 |

All-cause healthcare utilization

| Healthcare Utilization | Commercial/Medicare Supplemental | Medicaid | P-value\(^a\) |
|------------------------|----------------------------------|----------|---------------|
| Hospitalization, n (%) | 303 (51.4%)                      | 708 (51.2%) | 0.935 | 614 (45.0%) | 0.243 |
| Number of inpatient visits, mean (SD) | 1.1 (1.7) | 1.2 (1.8) | 0.670 | 1.1 (2.0) | 0.162 |
| LOS, mean (SD)         | 5.2 (12.5)                       | 6.5 (18.2) | 0.081 | 5.0 (15.3) | 6.7 (19.8) | 0.030 |
| ER visits, n (%)       | 333 (56.4%)                      | 966 (69.8%) | <0.001 | 420 (64.9%) | 398 (71.3%) | <0.001 |
| Number of ER visits, mean (SD) | 1.6 (2.4) | 2.1 (3.2) | <0.001 | 2.3 (3.4) | 3.4 (5.2) | <0.001 |
| Physician office visits, n (%) | 588 (99.7%)                      | 1361 (98.3%) | 0.016 | 1310 (96.0%) | 0.006 |
| Number of physician office visits, mean (SD) | 10.9 (7.4) | 10.2 (7.6) | 0.061 | 10.7 (7.9) | 8.9 (7.2) | <0.001 |
| Neurologist visit, n (%) | 378 (61.4%)                      | 878 (63.4%) | 0.791 | 67 (10.4%) | 135 (19.9%) | 0.746 |
| Number of neurologist visits, mean (SD) | 2.2 (2.5) | 1.9 (2.3) | 0.010 | 0.4 (1.5) | 0.3 (1.1) | 0.082 |
| PCP visit, n (%)       | 268 (45.4%)                      | 852 (61.6%) | <0.001 | 321 (49.6%) | 712 (52.2%) | 0.286 |
### Table 4. (Continued).

|                          | Commercial/Medicare Supplemental | Medicaidb | P-value
|--------------------------|----------------------------------|-----------|----------
|                          | Clobazam | Non-clobazam | N = 590 | N = 1384 |  | Clobazam | Non-clobazam | N = 647 | N = 1365 |  |
| Number of PCP visits, mean (SD) | 2.1 (4.0) | 3.2 (4.6) | <0.001 | 3.1 (5.1) | 3.4 (5.2) | 0.253 |
| Laboratory visits, n (%) | 406 | 68.8% | 379 | 58.6% | 747 | 54.7% | 0.104 |
| Number of laboratory visits, mean (SD) | 2.3 (3.0) | 1.9 (3.0) | 0.012 | 1.7 (3.9) | 1.8 (3.5) | 0.726 |
| Radiology visits, n (%) | 255 | 43.2% | 254 | 39.3% | 621 | 45.5% | 0.008 |
| Number of radiology visits, mean (SD) | 0.9 (1.5) | 1.4 (2.9) | <0.001 | 0.7 (1.2) | 1.0 (1.7) | <0.001 |
| Other outpatient visits, n (%) | 90.9 (91.4) | 63.9 (87.7) | <0.001 | 640 | 98.9% | 1335 | 97.8% | 0.082 |
| Number of other outpatient visits, mean (SD) | 33.0 (52.3) | 18.1 (31.3) | <0.001 | 90.9 (91.4) | 63.9 (87.7) | <0.001 |

Notes: ER – emergency room; LOS – length of stay; PCP – primary care physician; SD – standard deviation; USD – United States dollars.  
<sup>a</sup> P < 0.05; P-values were obtained using Chi-square tests for categorical variables and t-tests for continuous variables.  
<sup>b</sup> The majority of claims do not have information on physician specialty.

Bold text indicates a statistically significant difference with a p-value < 0.05.

### Table 5. Baseline healthcare costs of commercial/Medicare Supplemental patients and Medicaid patients.

|                          | Commercial/Medicare Supplemental | Medicaidb | P-value
|--------------------------|----------------------------------|-----------|----------
|                          | Clobazam | Non-clobazam | N = 590 | N = 1384 |  | Clobazam | Non-clobazam | N = 647 | N = 1365 |  |
| Annual seizure-related costs in 2014 USD, mean (SD) | $33,478 (58,431) | $12,709 (36,420) | <0.001 | $23,219 (84,306) | $7687 (25,092) | <0.001 |
| Medical | $24,066 (56,142) | $10,563 (35,194) | <0.001 | $15,544 (82,673) | $5951 (22,374) | 0.010 |
| Hospitalization | $15,013 (48,020) | $7,366 (30,951) | <0.001 | $10,016 (80,795) | $4,108 (22,651) | <0.001 |
| ER | $561 (3549) | $593 (2314) | 0.933 | $507 (3549) | $593 (2314) | 0.933 |
| Physician office | $1,881 (3,770) | $562 (1,438) | <0.001 | $6,454 (1,675) | $2,46 (699) | <0.001 |
| Neurologist | $164 (577) | $214 (363) | <0.001 | $33 (149) | $5 (80) | 0.085 |
| PCP | $115 (382) | $51 (190) | 0.077 | $57 (375) | $4 (212) | 0.593 |
| Laboratory | $250 (1434) | $582 (621) | <0.001 | $27 (178) | $76 (98) | <0.001 |
| Radiology | $166 (805) | $126 (632) | 0.138 | $57 (375) | $4 (212) | 0.593 |
| Other outpatient | $6015 (22,108) | $1634 (31,553) | <0.001 | $4,981 (16,426) | $1186 (8086) | <0.001 |
| Prescription | $491 (12,416) | $2416 (5596) | <0.001 | $7676 (12,866) | $1736 (4262) | <0.001 |

Notes: ER – emergency room; LOS – length of stay; PCP – primary care physician; SD – standard deviation; USD – United States dollars.  
<sup>a</sup> P < 0.05; P-values for differences in cost were obtained using the Wilcoxon-Mann-Whitney test.  
<sup>b</sup> The majority of claims do not have information on physician specialty.

Bold text indicates a statistically significant difference with a p-value < 0.05.

---

### Baseline all-cause resource utilization and costs

Commercial/Medicare Supplemental clobazam users had higher all-cause resource utilization and associated costs, on average, over the 12-month pre-index period compared to non-clobazam users (Tables 4 and 5). Higher proportions of clobazam users had at least one physician office visit (99.7% vs 98.3%, P = 0.016) and laboratory visit (68.8% vs 62.9%, P = 0.012) any time during the pre-index period compared to non-clobazam users. However, the proportion of patients with at least one all-cause ER visit (56.4% vs 69.8%, P < 0.001) and radiology visit (43.2% vs 55.5%, P < 0.001) was lower among clobazam users than non-clobazam users. The average number of neurologist visits (2.2 ± 2.5 vs 1.9 ± 2.3, P = 0.010), laboratory visits (2.3 ± 3.0 vs 1.9 ± 3.0, P = 0.002), and other outpatient visits (33.0 ± 52.3 vs 18.1 ± 31.3, P < 0.001) was higher for clobazam users than non-clobazam users. Average annual pre-index all-cause total ($73,486 ± $110,918 vs $49,632 ± $89,843, P < 0.001), medical ($58,116 ± $100,102 vs $43,292 ± $86,376, P < 0.001), and prescription ($15,370 ± $36,617 vs $18,940, P < 0.001) costs were significantly higher for clobazam users compared to non-clobazam users.

Overall, Medicaid clobazam users also had higher all-cause resource utilization and total all-cause costs, on average, over the 12-month pre-index period compared to non-clobazam users (Tables 4 and 5).
Treatment patterns: clobazam and non-clobazam users

Clinically and statistically significant differences were observed between the baseline demographic and clinical profiles of clobazam and non-clobazam users. Therefore, adjustments to ameliorate selection bias prior to comparison of outcomes were required. Assessment of the standardized mean differences after applying the standardized mortality ratio weighting showed that many of the baseline characteristics remained unbalanced between the cohorts. Additional assessments were performed including limiting the study population and matching on few variables before the standardized mortality ratio weighting; however, regardless of method, the baseline characteristics between the clobazam and non-clobazam cohorts remained unbalanced (results not shown). Therefore, no meaningful statistical inference can be drawn on the comparison of the clobazam and non-clobazam users, so only univariate analyses were performed and reported for the assessment of treatment patterns.

Among the Commercial/Medicare Supplemental population, over the six months post-index, clobazam users had, on average, 5.5 (±2.6) clobazam prescription fills and stayed on treatment for an average of 140 (±50.8) days and on all AED treatment for an average of 166.0 (±29.6) days (Table 6). Non-clobazam users had, on average, 4.6 (±2.8) index prescription fills and stayed on index treatment for an average of 119.5 (±62.6) days and on all AED treatment for an average of 138.4 (±54.0) days over the six months of the post-index period. Assessment of changes to the index therapy showed that within the clobazam cohort, 11.4% augmented, 27.5% discontinued, and 56.3% continued clobazam therapy. Among the non-clobazam users, 9.2% augmented, 38.4% discontinued, and 45.9% continued their index therapy. Approximately 11.5% of clobazam users and 33.1% of non-clobazam users discontinued all AED therapy during the six-month post-index period. Results over 12-months post-index treatment were consistent with the six-month results.

Among Medicaid patients, clobazam users had, on average, 5.7 (±2.6) index prescription fills and stayed on clobazam for an average of 138.7 (±51.5) days and on any AED for an average of 143.7 (±33.3) days over the six months of the post-index period (Table 6). Non-clobazam users had, on average, 4.6 (±2.7) index prescription fills and stayed on their index AED for an average of 138.4 (±56.8) days over the six months of the post-index period. Assessment of changes to the index AED showed that among clobazam users, 10.1% augmented, 25.0% discontinued, and 60.3% continued clobazam therapy. Among the non-clobazam users, 8.1% augmented, 39.9% discontinued, and 45.6% continued their index AED. Similar proportions of the clobazam and non-clobazam users in the Medicaid population discontinued all AED therapy; again, the 12-month results were consistent with the six-month results.

Healthcare resource utilization and costs: clobazam: pre- vs post-clobazam treatment

Of the 590 Commercial and Medicare Supplemental (647 Medicaid) clobazam users, 314 (358 Medicaid) were continuously enrolled in medical and pharmacy claims for at least 12 months post-index and had at

| Table 6. Treatment patterns of commercial/Medicare Supplemental patients and Medicaid patients. |
|---------------------------------------------------------------|
| **Treatment Patterns**                                       | **Commercial/Medicare Supplemental** | **Medicaid** |
| Number of index AED prescription claims, mean (SD)           | N = 590 | N = 1384 | N = 647 | N = 1365 |
| Total days on index AED, mean (SD)                           | 5.5 (2.6) | 4.6 (2.8) | 5.7 (2.6) | 4.6 (2.7) |
| Changes to index treatment, n (%)                            | 140.1 (50.8) | 119.5 (62.6) | 138.7 (51.5) | 114.1 (64.3) |
| Augmentation                                                  | 67 | 11.4% | 127 | 9.2% | 65 | 10.1% | 111 | 8.1% |
| Switching                                                     | 27 | 4.9% | 91 | 6.6% | 30 | 4.6% | 86 | 6.3% |
| Discontinuation                                               | 62 | 27.5% | 531 | 38.4% | 162 | 25.0% | 545 | 39.9% |
| Continued index therapy                                       | 332 | 56.3% | 635 | 45.9% | 390 | 60.3% | 623 | 45.6% |
| Time to change in index treatment in days, mean (SD)         |  |  |  |  |  |  |  |
| Time to augmentation                                         | 60.8 (50.2) | 49.6 (55.6) | 70.6 (58.0) | 59.3 (63.1) |
| Time to switch                                                | 76.2 (50.9) | 69.0 (51.0) | 99.4 (47.0) | 59.0 (46.1) |
| Time to discontinuation                                       | 60.4 (36.8) | 47.9 (35.4) | 55.0 (33.6) | 45.1 (36.9) |
| Total days on any AED, mean (SD)                             | 166.0 (29.6) | 138.4 (54.0) | 164.4 (33.3) | 134.5 (56.8) |
| All AED discontinuation rate, n (%)                          | 68 | 11.5% | 458 | 33.1% | 72 | 11.1% | 462 | 33.8% |
| Time to discontinuation from all AEDs, mean (SD)             | 71.4 (37.9) | 52.3 (36.6) | 62.4 (35.0) | 49.5 (38.3) |

Notes: AED – antiepileptic drug; SD – standard deviation.

* Eight AEDs were considered in the study.
least one clobazam prescription between 6 and 12 months post-index. Seizure-related and all-cause healthcare utilization data for the 12-month pre- and post-clobazam initiation periods are presented in Figures 2–5, while associated costs are presented in Table 7.

Seizure-related resource utilization and costs
The proportions of patients hospitalized (38.2% vs 30.9%, \( P = 0.032 \)) and receiving ER care (31.9% vs 18.5%, \( P < 0.001 \)) post-clobazam initiation were lower compared with the period prior to clobazam initiation among the Commercial and Medicare Supplemental population (Figure 2). The mean numbers of seizure-related inpatient stays (0.7 ± 1.3 vs 0.5 ± 1.1, \( P = 0.008 \)), ER visits (0.7 ± 1.4 vs 0.4 ± 1.2, \( P < 0.001 \)), and neurologist visits (2.0 ± 2.3 vs 1.7 ± 2.0, \( P = 0.011 \)) were also significantly lower post-clobazam initiation (Figure 3). Finally, the mean number of unique concomitant AED agents (excluding clobazam) decreased post-clobazam initiation (1.7 ± 1.1 vs 1.5 ± 1.0, \( P < 0.001 \)).

Average annual seizure-related medical costs were significantly lower post-clobazam initiation ($23,740 ± $52,288 vs $19,958 ± $43,090, \( P = 0.004 \)), driven by lower seizure-related ER ($908 ± $2612 vs $662 ± $3441, \( P = 0.002 \)) and physician office visit ($1873 ± $4673 vs $1278 ± $1981, \( P = 0.005 \)) costs (Table 7). However, there were significantly higher seizure-related prescription costs in the post-index period ($9549 ± $12,578 vs $15,125 ± $13,735, \( P < 0.001 \)), which resulted in significantly higher average annual seizure-related total costs compared to before initiation ($33,289 ± $54,938 vs $35,083 ± $46,149, \( P = 0.029 \)).

Among Medicaid patients, similar trends in seizure-related resource utilization and costs were observed over the 12 months post-clobazam initiation compared to pre-clobazam initiation. However, while the proportion of patients with lab visits did not differ, and average
utilization for other outpatient services significantly increased post-clobazam initiation. Also in this population, the reduction in medical costs was driven predominantly by a reduction in seizure-related hospitalization costs.

**All-cause resource utilization and costs**

In the 12 months following clobazam initiation, there were no significant differences in the proportions of Commercial and Medicare Supplemental patients with all-cause resource utilization in specific settings compared with the 12 months prior to clobazam initiation (Figure 4). The mean number of neurologist visits (2.4 ± 2.5 vs 2.0 ± 2.2, P = 0.003) and PCP visits over 12 months significantly decreased (2.1 ± 4.1 vs 1.7 ± 3.2, P = 0.009) post-clobazam initiation compared with pre-clobazam initiation, while the number of other outpatient visits increased (33.4 ± 53.4 vs 38.9 ± 60.9, P = 0.004) (Figure 5).

Average annual all-cause medical costs were not significantly different post-clobazam initiation ($57,090 ± $107,206 vs $59,292 ± $93,302, P = 0.411) (Table 7). However, there were significantly higher all-cause prescription costs post-clobazam initiation ($16,229 ± $35,832 vs $22,098 ± $44,556, P < 0.001), resulting in significantly higher average annual all-cause total costs compared to pre-clobazam initiation ($73,319 ± $117,534 vs $81,389 ± $110,776, P < 0.001).

Among Medicaid patients, the proportion of patients with at least one hospitalization and neurologist visit significantly decreased from pre- to post-
Table 7. Pre-index and post-index healthcare costs among clobazam patients in the commercial/Medicare Supplemental and Medicaid populations.

|                     | Commercial/Medicare Supplemental (N = 314) | Medicaid (N = 358) | P-value* |
|---------------------|---------------------------------------------|-------------------|----------|
|                     | Pre-clobazam | Post-clobazam | Pre-clobazam | Post-clobazam | |
| Healthcare costs    |               |               |               |               | |
| Annual seizure-related costs in 2014 USD, mean (SD) |               |               |               |               | |
| Total               | $33,289 (54,938) | $35,083 (46,149) | 0.029 | $27,541 (109,816) | $28,493 (44,016) | <0.001 |
| Medical             | $23,740 (52,288) | $19,958 (43,090) | 0.004 | $18,965 (108,221) | $14,442 (39,754) | 0.036 |
| Hospitalization     | $13,711 (41,266) | $11,639 (32,128) | 0.094 | $12,608 (106,674) | $7805 (35,724) | 0.006 |
| ER                  | $908 (2612) | $662 (3441) | 0.002 | $304 (892) | $196 (502) | 0.003 |
| Physician office    | $1873 (4673) | $1278 (1981) | 0.005 | $728 (1422) | $657 (1485) | 0.001 |
| Neurologist         | $448 (672) | $355 (508) | 0.022 | $30 (142) | $17 (77) | 0.100 |
| PCP                 | $116 (391) | $81 (298) | 0.072 | $76 (212) | $65 (194) | 0.303 |
| Laboratory          | $397 (1385) | $270 (1026) | 0.177 | $34 (226) | $46 (324) | 0.378 |
| Radiology           | $124 (689) | $92 (476) | 0.366 | $58 (456) | $29 (181) | 0.336 |
| Other outpatient    | $6727 (25,573) | $6018 (20,393) | 0.733 | $5234 (17,472) | $5708 (17,619) | 0.263 |
| Prescription        | $9549 (12,578) | $15,125 (13,735) | <0.001 | $8576 (14,444) | $14,051 (16,375) | <0.001 |
| Annual all-cause costs in 2014 USD, mean (SD) |               |               |               |               | |
| Total               | $73,319 (117,534) | $81,389 (102,307) | 0.001 | $68,565 (150,749) | $73,153 (102,307) | <0.001 |
| Medical             | $57,090 (107,206) | $59,216 (93,302) | 0.411 | $52,667 (131,965) | $59,397 (89,727) | 0.080 |
| Hospitalization     | $28,079 (84,526) | $29,097 (57,815) | 0.308 | $20,860 (124,848) | $18,809 (70,923) | 0.506 |
| ER                  | $32,288 (7792) | $31,288 (9189) | 0.102 | $13,822 (2718) | $11,914 (2122) | 0.421 |
| Physician office    | $4984 (8060) | $4243 (5961) | 0.076 | $2596 (3365) | $2431 (3329) | 0.024 |
| Neurologist         | $546 (763) | $457 (686) | 0.013 | $50 (290) | $23 (113) | 0.055 |
| PCP                 | $456 (1317) | $311 (777) | 0.060 | $235 (447) | $236 (423) | 0.509 |
| Laboratory          | $725 (1965) | $580 (1525) | 0.294 | $111 (333) | $130 (516) | 0.309 |
| Radiology           | $471 (1467) | $341 (978) | 0.214 | $203 (715) | $131 (404) | 0.028 |
| Other outpatient    | $19,603 (47,316) | $21,903 (48,312) | 0.073 | $27,516 (37,829) | $30,242 (40,282) | 0.092 |
| Prescription        | $16,229 (35,832) | $22,098 (44,556) | <0.001 | $15,898 (58,577) | $20,215 (36,680) | <0.001 |

Notes: ER – emergency room; PCP – primary care physician; SD – standard deviation; USD – United States dollars.

*P-values in bold <0.05. P-values for unadjusted differences in categorical variables were obtained using McNemar’s test to account for pre-post design. Similarly, P-values for count variables were obtained using paired t-tests. P-values for difference in median costs were obtained using Wilcoxon signed-rank test (non-parametric version of a paired t-test) and P-values for difference in median costs were obtained using Wilcoxon signed rank test. Bold text indicates a statistically significant difference with a p-value < 0.05.

Clobazam initiation. Post-clobazam initiation, the average number of ER visits, physician office visits, and neurologist visits decreased, while the number of other outpatient visits increased compared to pre-clobazam. The all-cause costs trend from the pre-clobazam period to the post-clobazam period was similar to that for the Commercial and Medicare Supplemental patients.

Discussion

This study demonstrated that there are key differences in the demographic and clinical characteristics of probable LGS patients initiating treatment with clobazam compared to those initiating other AEDs in both the Commercial/Medicare Supplemental and Medicaid populations under study. Treatment patterns associated with the index AED and overall AED use also differed between these patients. In addition, among patients treated with clobazam, both seizure-related healthcare utilization and its associated medical costs declined when compared to an equivalent 12-month period prior to treatment initiation.

Patients who initiated treatment with clobazam were younger and received more seizure-related clinical care prior to treatment initiation than those who initiated treatment with alternative AEDs. Prior to treatment initiation, clobazam patients also had higher seizure-related healthcare utilization and incurred both higher all-cause and seizure-related costs compared to those treated with other AEDs. Results were presented for the overall population due to the similar trend observed when clobazam and non-clobazam patients were compared in pediatric and adult cohorts (analysis not presented).

Several statistical methods were employed in an attempt to create comparability between the baseline characteristics of the clobazam and non-clobazam cohorts; however, none were successful. These results highlight that LGS patients enrolled in this sample of employer-sponsored and Medicaid benefit plans and initiating clobazam treatment compared to other AED treatments during the same time period have greater disease severity, which suggests a physician prescribing preference for clobazam in LGS patients who have more severe epilepsy. Similar findings were observed in a database study conducted in adult epilepsy patients in the United Kingdom (UK). In that study, prior to treatment initiation,
patients initiating clobazam treatment were younger and had greater use of concomitant AEDs than those receiving clonazepam [15].

Treatment pattern results were not statistically compared between the clobazam and non-clobazam cohorts due to the differences described; however, the unadjusted results indicate that patients treated with clobazam discontinued or switched treatment less often and stayed on treatment longer relative to patients initiating treatment with alternative AEDs. The lower rate of treatment discontinuation and switch among the clobazam users may be due to better treatment benefit with clobazam, resulting in patients remaining on treatment longer. Adverse events profile of these drugs might have also affected the rate of treatment discontinuation and switch. Treatment patterns in LGS patients have not been extensively evaluated; although in the UK study noted above, treatment duration differed from that reported in the current study [15]. The median treatment duration was similar between the epilepsy patients treated with clobazam or clonazepam. The observed differences could be a result of the duration of follow-up; the current study evaluated treatment patterns over both a 6- and 12-month period, while average follow-up in the UK study was at least five years.

Among patients treated with clobazam, healthcare resource utilization and its associated costs were compared among clobazam users at 12 months pre- and post-clobazam initiation. Results showed that all-cause and seizure-related resource utilization was significantly reduced post-clobazam initiation. Higher prescription costs post-clobazam initiation was mostly offset by the reduction in medical costs, due in part to a reduction in seizure-related hospitalizations and ER visits. These results are also consistent with previous findings that clobazam could have a positive overall economic impact through decreased seizure-related medical costs [11,12].
In addition to decreased seizure-related medical costs, clobazam may also have an impact on indirect costs, such as decreased caregiver time, resulting in less productivity loss, and decreased long-term disability due to head injury for children [16].

This study has inherent limitations due to the use of claims data. There is no specific ICD-9-CM diagnosis code for LGS, and while the patient identification algorithm used in this investigation was based on previously published criteria and clinical opinion, misclassification of LGS patients might still be present. However, our results still provide valuable insight into the use of AED and impact of clobazam on costs in LGS patients. Baseline characteristics of clobazam and non-clobazam users indicate that these are patients with different disease severity, and statistical methods employed to remove these differences were unsuccessful. As a result, differences in post-index measures could not be evaluated between the clobazam and non-clobazam cohorts. Furthermore, clinical data are unavailable in the database; therefore, clinical observations that might influence physicians to prescribe one AED vs another could not be evaluated, and instead proxy measures of baseline disease severity and comorbidity were used. Another limitation is the pre- and post-treatment design, which has a potential for regression to the mean effect. However, this bias is more likely to occur when there is a treatment switch during an acute episode, such as in schizophrenia [17], than in the case of LGS, a chronic condition in which clobazam is often added to existing treatments. Finally, since the analysis focused on burden specific to medical resource use, it provides no insight into the relative impact of clobazam and other AEDs with respect to

---

**Figure 5.** Mean number of all-cause healthcare services utilized pre- vs post-clobazam. Notes: ER – emergency room; PCP – primary care physician. \( P \)-values in bold < 0.05. \( P \)-values for count variables were obtained using paired \( t \)-tests to account for pre-post design.
clinically important outcomes such as patient quality of life, activities of daily living, and caregiver burden.

Conclusions

Baseline comparisons suggest a prescribing preference for clobazam in LGS patients with more severe disease, regardless of whether the patient has healthcare benefits provided through private or public payers. The inability to eliminate selection bias further emphasizes the differences between the clobazam and non-clobazam treated cohorts. Regardless, clobazam users did have significant improvement in seizure-related resource utilization and medical costs post-clobazam initiation compared to the year prior to clobazam initiation.

Disclosure statement

Clément François and Vivienne Shen are employees of Lundbeck, LLC. John Stern is a consultant for Lundbeck, LLC. Augustina Ogbonnaya, Tasneem Lokhandwala, Pamela Landsman-Blumberg, Amy Duhig, and Robin Tan are employees of Xcenda, LLC.

Funding

This study was funded by Lundbeck, LLC. Xcenda, LLC received funding from Lundbeck to conduct this study and develop the manuscript.

ORCID

Tasneem Lokhandwala http://orcid.org/0000-0002-1983-9557

References

[1] Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82–93.
[2] Camfield PR. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia. 2011;52(Suppl 5):3–9.
[3] Crumrine PK. Lennox-Gastaut syndrome. J Child Neurol. 2002;17(Suppl 1):570–575.
[4] Markand ON. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol. 2003;20(6):426–441.
[5] van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat. 2008;4(6):1001–1019.
[6] Camfield P, Camfield C. Epileptic syndromes in childhood: clinical features, outcomes, and treatment. Epilepsia. 2002;43(Suppl 3):27–32.
[7] Gallop K, Wild D, Nixon A, et al. Impact of Lennox-Gastaut Syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review. Seizure. 2009;18(8):554–558.
[8] Montours GD, Wheless JW, Glauser TA. The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome. Epilepsia. 2014;55(Suppl 4):10–20.
[9] Sugai K. Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan. Epilepsia. 2004;45(Suppl 8):20–25.
[10] Ng YT, Conry J, Mitchell WG, et al. Clobazam is equally safe and efficacious for seizures associated with Lennox-Gastaut syndrome across different age groups: post hoc analyses of short- and long-term clinical trial results. Epilepsy Behav. 2015;46:221–226.
[11] Clements KM, Skornicki M, O’Sullivan AK. Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome. Epilepsy Behav. 2013;29(1):184–189.
[12] Skornicki M, Clements KM, O’Sullivan AK. Budget impact analysis of antiepileptic drugs for Lennox-Gastaut syndrome. J Manag Care Spec Pharm. 2014;20(4):400–406.
[13] 2015 Truven Health Analytics MarketScan® Research Databases. Commercial claims and encounters, Medicare supplemental and coordination of benefits, and Medicaid databases data dictionary [subscription access]; [cited 2016 Apr 8]. Available from: http://truvenhealth.com/your-healthcare-focus/analytics-research/marketscan-research-databases
[14] Stürmer T, Wyss R, Glynn RJ, et al. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014;275(6):570–580.
[15] Brodie MJ, Chung S, Wade A, et al. Clobazam and clonazepam use in epilepsy: results from a UK database incident user cohort study. Epilepsy Res. 2016;123:68–74.
[16] Gao L, Xia L, Pan SQ, et al. Burden of epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for epilepsy. Epilepsy Res. 2015;110:146–156.
[17] Gianfrancesco F, Wang RH, Mahmoud R, et al. Methods for claims-based pharmacoeconomic studies in psychosis. Pharmacoeconomics. 2002;20(8):499–511.